A Phase 2, Randomized, Double-Blind, Placebo-controlled study to evaluate the safety, tolerability, biological activity, and PK of ND-L02-s0201 in subjects with idiopathic pulmonary fibrosis (IPF)

The PI of this project was: Keith Meyer, MD

This project was funded by: sponsor (Nitto Denko)

The term of this project was: March 2018 to July 2019

The number of subjects scanned during this project was: 5